Tasigna

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Gastrointestinal Stromal Tumors, Leukemia, Myeloid, Accelerated Phase + 4 more

Treatment

2 Active Studies for Tasigna

What is Tasigna

Nilotinib

The Generic name of this drug

Treatment Summary

Nilotinib, also known as AMN107, is a drug being studied as a possible treatment for chronic myelogenous leukemia (CML). In a clinical trial in 2006, it was found to be safe and effective in cases of CML that had become resistant to the current first-line treatment, imatinib (Gleevec).

Tasigna

is the brand name

image of different drug pills on a surface

Tasigna Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tasigna

Nilotinib

2007

3

Effectiveness

How Tasigna Affects Patients

Nilotinib is a drug that stops certain proteins from working, which can help treat different types of leukemia, including chronic myeloid leukemia (CML).

How Tasigna works in the body

Nilotinib stops the BCR-ABL protein from causing Chronic Myelogenous Leukaemia (CML). It is able to do this by fitting into the ATP-binding site of the BCR-ABL protein with greater affinity than other drugs. It can also treat other types of leukaemia, mastocytosis, and gastrointestinal stromal tumours by inhibiting the c-Kit receptor kinase.

When to interrupt dosage

The recommended dose of Tasigna is contingent upon the diagnosed state, including refractory, accelerated phase Chronic myeloid leukemia, Gastrointestinal Stromal Tumors and Myeloid Leukemia, Chronic, Chronic Phase. The degree of dosage fluctuates as per the delivery approach featured in the table below.

Condition

Dosage

Administration

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

, 200.0 mg, 150.0 mg, 50.0 mg

, Oral, Capsule, Capsule - Oral

Gastrointestinal Stromal Tumors

, 200.0 mg, 150.0 mg, 50.0 mg

, Oral, Capsule, Capsule - Oral

Leukemia, Myeloid, Accelerated Phase

, 200.0 mg, 150.0 mg, 50.0 mg

, Oral, Capsule, Capsule - Oral

resistant to tyrosine kinase inhibitors

, 200.0 mg, 150.0 mg, 50.0 mg

, Oral, Capsule, Capsule - Oral

imatinib

, 200.0 mg, 150.0 mg, 50.0 mg

, Oral, Capsule, Capsule - Oral

imatinib

, 200.0 mg, 150.0 mg, 50.0 mg

, Oral, Capsule, Capsule - Oral

Leukemia, Myeloid, Chronic-Phase

, 200.0 mg, 150.0 mg, 50.0 mg

, Oral, Capsule, Capsule - Oral

Warnings

Tasigna Contraindications

Condition

Risk Level

Notes

Hypokalemia

Do Not Combine

Long QT Syndrome

Do Not Combine

Hypomagnesemia

Do Not Combine

There are 20 known major drug interactions with Tasigna.

Common Tasigna Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The metabolism of (R)-warfarin can be decreased when combined with Nilotinib.

(S)-Warfarin

Major

The metabolism of (S)-Warfarin can be decreased when combined with Nilotinib.

1,2-Benzodiazepine

Major

The metabolism of 1,2-Benzodiazepine can be decreased when combined with Nilotinib.

3,5-diiodothyropropionic acid

Major

The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Nilotinib.

5-androstenedione

Major

The metabolism of 5-androstenedione can be decreased when combined with Nilotinib.

image of a doctor in a lab doing drug, clinical research

Tasigna Novel Uses: Which Conditions Have a Clinical Trial Featuring Tasigna?

4 studies are presently being conducted to evaluate the effectiveness of Tasigna in treating Chronic Myeloid Leukemia, Chronic Phase, Gastrointestinal Stromal Tumors and Refractory, Accelerated Phase Chronic Myeloid Leukemia.

Condition

Clinical Trials

Trial Phases

Gastrointestinal Stromal Tumors

0 Actively Recruiting

imatinib

0 Actively Recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

0 Actively Recruiting

Leukemia, Myeloid, Accelerated Phase

0 Actively Recruiting

imatinib

0 Actively Recruiting

resistant to tyrosine kinase inhibitors

0 Actively Recruiting

Leukemia, Myeloid, Chronic-Phase

3 Actively Recruiting

Phase 2, Phase 1

Tasigna Reviews: What are patients saying about Tasigna?

5

Patient Review

3/7/2011

Tasigna for Chronic Phase Chronic Myeloid Leukemia

I experienced minimal side effects when starting this medication, which is incredible considering how effective it was. I had some nausea and headaches at first, but those quickly faded away.

5

Patient Review

6/5/2015

Tasigna for Chronic Phase Chronic Myeloid Leukemia

Within weeks of starting this treatment, I began to experience several uncomfortable side effects. My nipples became itchy and then painfully sore to the touch. Additionally, I started feeling tired all the time and my erections weakened. After some testing, it was determined that my testosterone levels were low so I started hormone therapy. However, even with increased dosages, my testosterone levels have continued to drop.

5

Patient Review

5/1/2010

Tasigna for Chronic Phase Chronic Myeloid Leukemia

This drug is very effective, but you have to be careful to follow the directions exactly. I made the mistake of consuming grapefruit products while on the second day and had a 8 hour blackout. After being on the drug for just 1 month, my H&H, RBC, & WBC are all in the normal range. I was previously on Gleevec for 9 years, but the cml grew resistant to it. I am feeling very positive about the results so far. You just need to get your body accustomed to it, then you are set.

5

Patient Review

2/19/2013

Tasigna for Philadelphia Chromosome Positive Chronic Myelocytic Leukemia

I was on Gleevac for eight years before I started seeing any signs that it might not be working as well. Tasigna had no negative side effects for me and I'm now in complete remission.

4.7

Patient Review

11/30/2014

Tasigna for Chronic Phase Chronic Myeloid Leukemia

I've been taking this drug for over 5 years. It's been an adjustment, but I'm grateful to be alive and in remission after 32 years with CML.

4.7

Patient Review

2/15/2013

Tasigna for Type of Leukemia - Chronic Myelogenous Leukemia

I'm thankful for this medication, especially after difficulties with gleevec. The only side effect I notice that my doctor dismisses is a loss of sense of smell; however, this began occurring when the only new medication I started taking was tasigna. They need to address this-- but regardless, I would still use the tasigna.

4.3

Patient Review

11/14/2011

Tasigna for Philadelphia Chromosome Positive Chronic Myelocytic Leukemia

I've been on this medication for three months and, unfortunately, have experienced more irregular heartbeats. This is especially scary for me because heart disease runs in my family. I was originally told to take the medicine an hour before or after eating, but now I'm reading that it should be the opposite. That may explain why going to sleep has been so frightening! Taking the medicine correctly would be a game changer for me.

4.3

Patient Review

5/20/2010

Tasigna for Type of Leukemia - Chronic Myelogenous Leukemia

Tasigna has been a much better experience than my previous two medications. However, I recently began having many health issues and only just realized that they were due to the listed side effects of this drug. Now, I'm facing an uphill battle to recover from these complications.

4

Patient Review

6/29/2011

Tasigna for Chronic Phase Chronic Myeloid Leukemia

Tasigna has been an absolute godsend and has put me into remission. However, I am experiencing some nasty side effects that my doctors claim are unrelated to the medication. These include stomach pain, thrush, fatigue, and more. It's really hard to deal with all of this without any support.

4

Patient Review

6/14/2013

Tasigna for Philadelphia Chromosome Positive Chronic Myelocytic Leukemia

I've been on this medication for nearly four years as part of a research project, and the side effects have been manageable. The main issue is that you have to take it on an empty stomach twelve hours apart, which can be difficult to work around meal times.

4

Patient Review

11/25/2009

Tasigna for Type of Leukemia - Chronic Myelogenous Leukemia

The nausea can be tough to deal with at times, but zofran helps me a lot.

3.7

Patient Review

1/18/2009

Tasigna for Type of Leukemia - Chronic Myelogenous Leukemia

I felt lightheaded and nauseous after taking this medication, and also experienced fatigue.

3

Patient Review

12/23/2011

Tasigna for Chronic Phase Chronic Myeloid Leukemia

The diet is tough to stick to.

1.3

Patient Review

2/25/2013

Tasigna for Type of Leukemia - Chronic Myelogenous Leukemia

This pill was tough to keep track of- I had to make sure I took it 12 hours apart and on an empty stomach. 29 days after starting the medication, I ended up in the hospital with pneumonia. The doctors think it might have been caused by the drug.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tasigna

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Tasigna a chemotherapy drug?

"novartis manufactures the oral chemotherapy drug tasigna, which was approved by the FDA in 2007. tasigna is prescribed to treat a specific type of blood cancer called philadelphia chromosome-positive chronic myeloid leukemia."

Answered by AI

What is the drug Tasigna used to treat?

"Nilotinib is a drug used to treat chronic myelogenous leukemia-CML, a form of blood cancer. It works by inhibiting the growth of cancer cells."

Answered by AI

What are the side effects of Tasigna?

"Low blood cell counts can cause decreased blood flow to the legs, heart, or brain. Pancreas inflammation (pancreatitis) can cause liver problems. Tumor lysis syndrome can cause bleeding problems. Fluid retention can cause abnormal growth or development in children."

Answered by AI

Can Tasigna cure CML?

"CML-CP is a type of leukemia that is characterized by the presence of the Philadelphia chromosome. TASIGNA is a TKI that has been used to treat approximately 28,000 people with this condition in the United States since it was approved in 2007. Some people may refer to this condition as a "good cancer," but in reality, there is no such thing."

Answered by AI

Clinical Trials for Tasigna

Image of The University of Texas MD Anderson Cancer Center in Houston, United States.

TERN-701 for Leukemia

18+
All Sexes
Houston, TX

The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML). The study has two parts: Part 1 of the trial (Dose Escalation) will evaluate sequential dose escalation cohorts of TERN-701 administered once daily. Part 2 (Dose Expansion) consists of randomized, parallel dose expansion cohorts of TERN-701 that will further evaluate the efficacy and safety of 2 recommended dose levels for expansion selected from Part 1. Part 2m (mutation cohort) will further evaluate the efficacy and safety of 500mg of TERN-701 in previously treated CP-CML participants with certain resistance mutations. In both Part 1 and Part 2, participants will receive continuous once daily dosing of TERN-701 divided into 28-day cycles. During the treatment period, participants will have scheduled visits to the trial center at Cycle 1 day 1(C1D1), C1D2 (Part 1 only), C1D8, C1D15, and C1D16 (Part 1 only), followed by Day 1 of Cycles 2 through 7, and Day 1 of every 3 cycles thereafter. Approximately 180 participants could be enrolled in this trial, up to 80 participants in Part 1 (dose escalation), including optional backfill cohorts, approximately 80 participants in Part 2 (randomized dose expansion), and approximately 20 participants in Part 2m (mutation cohort). All participants will receive active trial intervention. Four dose-level cohorts have been evaluated in Part 1; two dose levels will be evaluated in Part 2 (Randomized Dose Expansion), and one dose level will be evaluated in Part 2m (mutation cohort).

Phase 1 & 2
Recruiting

The University of Texas MD Anderson Cancer Center (+18 Sites)

Terns, Inc.